A recent documentary followed several people through the experience of starting, and eventually stopping, GLP-1 weight-loss injections. Their stories varied, but a common thread ran through them: starting the drug was straightforward. Deciding whether, when, and how to stop was not. That question is becoming relevant to a lot of people. A 2026 study from … Read more
Osteoarthritis has no cure. Current treatment manages pain and, eventually, replaces the joint. That is the backdrop against which a June 2026 study from Stanford Medicine drew significant attention. The findings are genuinely notable. They are also, at this stage, about mice and lab tissue, not people, and the gap between those two things is … Read more
For most of the history of cancer medicine, the advice given to patients during treatment was to rest. The logic seemed obvious: the body is under severe physiological stress, chemotherapy and radiation are exhausting, and pushing patients to exercise while managing these demands appeared counterproductive at best and dangerous at worst. That consensus has been … Read more
GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and related medications — have changed the landscape of weight management. Their efficacy is real and well-documented. But as tens of millions of people worldwide now use these drugs, a body of evidence is building around a problem that is not always flagged in the … Read more
A Cochrane review carries specific weight in the evidence hierarchy. Cochrane reviews are systematic meta-analyses that attempt to synthesise all available high-quality randomised trial evidence on a clinical question, applying rigorous methodology to minimise bias. When one lands on the question of exercise and depression — and finds that exercise reduces depressive symptoms to a … Read more